Measurement of factor VII and of activated factor VII in healthy individuals and in prothrombin complex concentrates

Thrombosis Research

Volumn 86, Issue 6, 1997, Pages 493-504

  Hellstern, Peter ^a   Beeck, Hannelore ^a   Fellhauer, Annette ^a   Fischer, Antje ^a   Faller Stöckl, Beate ^a  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

Activated factor VII; Factor VII amidolytic activity; Factor VII clotting activity; Preanalytical variables; Prothrombin complex concentrates; Reference ranges

Indexed keywords

BLOOD CLOTTING FACTOR 7; PROTHROMBIN COMPLEX;

ADULT; ANALYTIC METHOD; ARTICLE; BLOOD CLOTTING TEST; CONTROLLED STUDY; FEMALE; FREEZING; HUMAN; ISCHEMIC HEART DISEASE; MALE; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; REFERENCE VALUE; THAWING;

ADOLESCENT; ADULT; ANIMALS; BLOOD CHEMICAL ANALYSIS; FACTOR VII; FACTOR VIIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN; RABBITS; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 0030797612     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00098-4     Document Type: Article

References (30)

1. HEMKER H.C., MULLER A.D., GONGGRIJP R. The estimation of human blood coagulation factor VII. J Mol Med. 1:1976;127-134.
2. SELIGSON U., ØSTERUD B., RAPAPORT S.I. Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII. Blood. 52:1978;978-988.
3. KITCHEN S., MALIA R.G., PRESTON F.E. A comparison of methods for the measurement of activated factor VII. Thromb Haemost. 68:1992;301-305.
4. MILLER G.J., STIRLING Y., ESNOUF M.P., HEINRICH J., van de LOO J., KIENAST J., WU K.K., MORRISSEY J.H., MEADE T.W., MARTIN J.C., IMESON J.D., COOPER J.A., FINCH A. Factor VII-deficient substrate plasma depleted of protein C raise the sensitivity of the factor VII bio-assay to activated factor VII: an international study. Thromb Haemost. 71:1994;38-48.
5. KAIRO K., TAKEFUMI M., ASADA R., SAKATA T., KATO H., MIYATA T. The strong positive correlation between factor VII clotting activity using bovine thromboplastin and the activated factor VII level. Thromb Haemost. 73:1995;429-434.
6. Van DEIJK W.A., van DAM-MIERAS M.C.E., MULLER A.D., HEMKER H.C. Evaluation of a coagulation assay determining the activity state of factor VII in plasma. Haemostasis. 13:1983;192-197.
7. MILLER G.J., WALTER S.J., STIRLING Y., THOMPSON S.G., ESNOUF M.P., MEADE T.W. Assay of factor VII activity by two techniques; evidence for increased conversion of VII to VIIa in hyperlipidemia, with possible implications for ischaemic heart disease. Br J Haematol. 59:1985;249-258.
8. WILDGOOSE P., NEMERSON Y., HANSEN L.L., NIELSEN F.E., GLAZER S., HEDNER U. Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood. 80:1992;25-28.
9. MORRISSEY J.H., MACIK B.G., NEUENSCHWANDER P.F., COMP P.C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selevtively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
10. KAIRO K., MIYATA T., SAKATA T., MATSUO T., KATO H. Fluoregenic assay of activated factor VII. Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese. Arterioscler Thromb. 14:1994;265-274.
11. MEADE T.W., MELLOWS S., BROZOVIC M., MILLER G.J., CHAKRABARTI R.R., NORTH W.R.S., HAINES A.P., STIRLING Y., IMESON J.D., THOMPSON S.G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 2:1986;533-537.
12. MEADE T.W., RUDDOCK V., STIRLING Y., CHAKRABARTI R., MILLER G.J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet. 342:1993;1076-1079.
13. HEINRICH J., BALLEISEN L., SCHULTE H., ASSMANN G., van de LOO J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arteriocler Thromb. 14:1994;54-59.
14. CORTELLARO M., BOSCHETTI C., COFRANESCO E., ZANUSSI E., CATALANO M., de GAETANO G., GABRIELLI L., LOMBARDI B., SPECCHIA G., TAVAZZI L., TREMOLI E., della VOLPE A., POLLI E., PLAT study group The PLAT study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients. Principal results. Arterioscler Thromb. 12:1992;1063-1070.
15. FOLSOM A.R., WU K.K., SHAHER E., DAVIS C.E. for the Atherosclerosis Risk in Communities (ARIC) Investigator. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. Arterioscler Thromb. 13:1993;1829-1836.
16. HUBBARD A.R., BARROWCLIFFE T.W. Measurement of activated factor VII using soluble mutant tissue factor - proposal for standardization. Thromb Haemost. 72:1994;643-651.
17. MILLER G.J., BAUER K.A., BARZEGAR S., COOPER J.A., ROSENBERG R.D. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease. Thromb Haemost. 75:1996;767-771.
18. SCARABIN P.Y., VISSAC A.M., KIRZIN J.M., BOURGEAT P., AMIRAL J., AGHER R., GUIZE L. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arterioscler Thromb Vasc Biol. 16:1996;1170-1176.
19. FAIR D.S. Quantification of factor VII in the plasma of normal and warfarin treated individuals. Blood. 62:1983;784-791.
20. OFOSU F.A., CRAVEN S., DEWAR L., ANVARI N., ANDREW M., BLAJCHMAN M.A. Age-related changes in factor VII proteolysis in vivo. Brit J Haematol. 94:1996;407-412.
21. BALLEISEN L., BAILEY J., EPPING P.H., SCHULTE H., van de LOO J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. baseline data on the relation to age, gender, body weight, smoking, alcohol, pill-using and menopause. Thromb Haemost. 54:1985;475-479.
22. HOWARD P.R., BOVILL E.G., PIKE J., CHURCH W.R., TRACY R.P. Factor VII antigen levels in a healthy blood donor population. Thromb Haemost. 72:1994;21-27.
23. MARI D., MANNUCCI P.M., COPPOLA R., BOTTASSO B., BAUER K.A., ROSENBERG R.D. Hypergoagulability in cetenarians: the paradox of successful aging. Blood. 85:1995;3144-3149.
24. ARËNS R.A.S., COPPOLA R., POTENZA I., MANNUCCI P.M. The increase with age of the components of the tissue factor coagulation pathway is gender-dependent. Blood Coagul Fibrinolysis. 6:1995;433-437.
25. LUSHER J.M. Thrombogenicity associated with factor IX complex concentrates. Seminars in Hematology. 28(Suppl 6):1991;3-5.
26. GILES A.R., JOHNSTON M., HOOGENDOORN H., BLAJCHMAN M., HIRSH J. The thrombogenicity of prothrombin complex concentrates: I. The relationship between in vitro characteristics and in vivo thrombogenicity in rabbits. Thromb Res. 17:1980;353-366.
27. GRAY E., TUBBS J., THOMAS S., OATES A., BOISCLAIR M., KEMBALL-COOK G., BARROWCLIFFE T.W. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Thromb Haemost. 73:1995;675-679.
28. SELIGSON U., KASPER C.K., ØTERUD B., RAPAPORT S. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion. Blood. 53:1979;828-837.
29. RAPAPORT S.I., RAO L.U.M. The tissue factor pathway: how it has become a "prima ballerina" [Review]. Thromb Haemost. 74:1995;7-17.
30. HELLSTERN, P. and KÖHLER, M. Prothrombin complex concentrates (PCC) and thromboembolic complications. Ann Hematol 70 (Suppl I), A88, 1995. A88.